Trials / Conditions / Hereditary Tyrosinemia, Type I

Hereditary Tyrosinemia, Type I

9 registered clinical trials studyying Hereditary Tyrosinemia, Type I.

Status	Trial	Sponsor	Phase
Withdrawn	A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients NCT06227429	Swedish Orphan Biovitrum	—
Unknown	Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine NCT04113772	Sutphin Drugs	N/A
Unknown	Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study) NCT03446586	Yassin Abdelghaffar Charity Center for Liver Disease and Research	—
Completed	Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1) NCT02750345	Cycle Pharmaceuticals Ltd.	Phase 1
Completed	Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1) NCT02750332	Cycle Pharmaceuticals Ltd.	Phase 1
Completed	Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin NCT02750709	Cycle Pharmaceuticals Ltd.	Phase 1
Completed	Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1 NCT02323529	Swedish Orphan Biovitrum	Phase 3
Completed	Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care NCT02320084	Swedish Orphan Biovitrum	—
Completed	Taste and Palatability of Orfadin Suspension NCT01734889	Swedish Orphan Biovitrum	Phase 1